Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Magnetic Resonance Spectroscopy 24 Temozolomide 22 Specimen Handling 13 Radiotherapy 12 X-Rays 9 Biopsy 9 Radiation 8 trametinib 6 Phantoms, Imaging 6 Nuclear Medicine Department, Hospital 6 Bevacizumab 6 larotrectinib 4 erdafitinib 4 dabrafenib 4 abemaciclib 4 ulixertinib 3 palbociclib 3 olaparib 3 Surgical Procedures, Operative 3 Nivolumab 3 D2C7-(scdsFv)-PE38KDEL 3 Cyclophosphamide 3 vorasidenib 2 tipifarnib 2 tazemetostat 2 selpercatinib 2 pembrolizumab 2 mirdametinib 2 lutetium Lu 177 dotatate 2 ivosidenib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Glioma × Escitalopram × 90 days × Clear all

NCT03728673 2026-04-17

A Study Utilizing Escitalopram in Glioma Patients

University of Nebraska

Phase 2 Recruiting

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡